Boston Scientific reported a 7.5% increase in Q2 2026 net sales to $5.442 billion, surpassing guidance with adjusted EPS of $0.86, up from $0.75 last year. The company completed a $2 billion share repurchase and invested $1.5 billion in MiRus LLC, gaining a 34% stake in the biomaterials and implant developer. Strong sales growth was seen across segments and regions, with notable advances in cardiovascular and neuromodulation products. Boston Scientific remains confident in its long-term growth, driven by innovation and strategic investments, while guiding for moderate sales growth and adjusted EPS in Q3 and full year 2026.
Boston Scientific reported strong Q2 results with revenue of $5.442 billion and adjusted EPS of $0.86, surpassing analyst expectations. However, RBC Capital lowered the 2026 stock price target from $85 to $70 due to competitive pressures and a reduce...
Boston Scientific reported better-than-expected results for the second quarter, with adjusted earnings per share of $0.86 surpassing the $0.83 estimate and revenue of $5.442 billion beating the $5.37 billion forecast. The company saw a 7.5% increase ...
Belo Sun Mining Corp. announced the final dismissal of a civil public action filed by Brazil's Federal Public Defender's Office against its Volta Grande Gold Project. The lawsuit, which sought to suspend the project's licensing pending further indige...
